{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T22:02:36Z","timestamp":1771279356049,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"US Veterans administration","award":["5I01CX001753-05"],"award-info":[{"award-number":["5I01CX001753-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The mechanism of hypertension associated with erythropoiesis-stimulating agents in chronic kidney disease (CKD) is complex and remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, anemic hypertensive patients with CKD and well-controlled or mildly elevated BP as confirmed by 24-hour ABP monitoring were randomly assigned to either a waitlisted group or darbepoetin in a 1:1 ratio stratified by stages of albuminuria. The primary end point was the change in 24-hour diastolic ABP from baseline to 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We screened 1699 patients and randomized 27 patients of the planned 160. Mean age (SD) was 75 (8) years, mean hemoglobin 9.4 (0.6) g\/dL, mean clinic BP 124.4 (19.5)\/57.2 (11.4) mm Hg and was similar between groups. At 12 weeks there was 1.7 g\/dL (95% CI, 0.9-2.5 g\/dL) difference in hemoglobin between waitlisted and immediate start group. Within group change in diastolic 24-hour ABP in the waitlisted group was \u22121.91 mm Hg and the immediate start group was +1.07 mm Hg. The difference in the changes was 2.98 mm Hg (95% CI, \u22121.36 to 7.31), P\u2009=\u2009.18. Comparing SBP, endothelial function, and UACR in the waitlisted and immediate start groups showed no significant differences between groups. However, within the waitlisted group UACR increased 35% from baseline (95% CI, 11%-82%) with darbepoetin exposure. Cardiovascular and atherothrombotic serious adverse events were more frequent during darbepoetin exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among anemic CKD patients with reasonably controlled hypertension, exposure to darbepoetin did not change 24-hour ABP or endothelial function. However, increase in albuminuria and serious adverse events during exposure to darbepoetin is a cause for concern and requires larger studies to affirm or refute these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajh\/hpaf200","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:10:36Z","timestamp":1759320636000},"page":"441-451","source":"Crossref","is-referenced-by-count":0,"title":["Erythropoietin-induced Hypertension in Chronic Kidney Disease\u2014A Mechanistic Randomized Controlled Trial"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"first","affiliation":[{"name":"Richard L. Roudebush VA Medical Center and Indiana University , Indianapolis, IN,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2026021616021099200_hpaf200-B1","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"2026021616021099200_hpaf200-B2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1681\/ASN.V24927","article-title":"Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin","volume":"2","author":"Abraham","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"2026021616021099200_hpaf200-B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.ndt.a091989","article-title":"Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic hemodialysis patients","volume":"7","author":"van de Borne","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"2026021616021099200_hpaf200-B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000168267","article-title":"Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian erythropoietin study group","volume":"11","author":"Burgess, ED","year":"1991","journal-title":"Am J Nephrol"},{"key":"2026021616021099200_hpaf200-B5","first-page":"S98","article-title":"The long-term effects of recombinant human erythropoietin on the cardiovascular system","volume":"38(Suppl 1)","author":"Eschbach","year":"1992","journal-title":"Clin Nephrol"},{"key":"2026021616021099200_hpaf200-B6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0895-7061(95)00035-N","article-title":"Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients","volume":"8","author":"Lebel","year":"1995","journal-title":"Am J Hypertens"},{"key":"2026021616021099200_hpaf200-B7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2215\/CJN.05040908","article-title":"Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA)","volume":"4","author":"Krapf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021616021099200_hpaf200-B8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2026021616021099200_hpaf200-B9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021616021099200_hpaf200-B10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021616021099200_hpaf200-B11","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2026021616021099200_hpaf200-B12","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/ndt\/gfx3244712017","article-title":"Mechanisms and mediators of hypertension induced by erythropoietin and related molecules","volume":"33","author":"Agarwal","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026021616021099200_hpaf200-B13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/ki.1995.354","article-title":"Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure","volume":"48","author":"Hand","year":"1995","journal-title":"Kidney Int"},{"key":"2026021616021099200_hpaf200-B14","first-page":"623","article-title":"Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis","volume":"14","author":"Yamakado","year":"1991","journal-title":"Clin Invest Med"},{"key":"2026021616021099200_hpaf200-B15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1161\/HYPERTENSIONAHA.107.090423","article-title":"Prevention of erythropoietin-associated hypertension","volume":"50","author":"Lee","year":"2007","journal-title":"Hypertension"},{"key":"2026021616021099200_hpaf200-B16","first-page":"E113","article-title":"Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure","volume":"271","author":"Vaziri","year":"1996","journal-title":"Am J Physiol"},{"key":"2026021616021099200_hpaf200-B17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jch.12961","article-title":"Assessing the accuracy of the OMRON HEM-907XL oscillometric blood pressure measurement device in patients with nondialytic chronic kidney disease","volume":"19","author":"Cohen","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2026021616021099200_hpaf200-B18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.0000150859.47929.8e","article-title":"Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American heart association council on high blood pressure research","volume":"45","author":"Pickering","year":"2005","journal-title":"Hypertension"},{"key":"2026021616021099200_hpaf200-B19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.kint.2018.08.021","article-title":"Minimally sufficient numbers of measurements for validation of 24-hour blood pressure monitoring in chronic kidney disease","volume":"94","author":"Agarwal","year":"2018","journal-title":"Kidney Int"},{"key":"2026021616021099200_hpaf200-B20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","article-title":"Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force","volume":"39","author":"Corretti","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026021616021099200_hpaf200-B21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/10641969509037420","article-title":"Pressor effect of recombinant human erythropoietin: results of ambulatory blood pressure monitoring and home blood pressure measurements","volume":"17","author":"Imai","year":"1995","journal-title":"Clin Exp Hypertens"},{"key":"2026021616021099200_hpaf200-B22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1523-1755.1999.00531.x","article-title":"Effects of normal hematocrit on ambulatory blood pressure in epoetin- treated hemodialysis patients with cardiac disease","volume":"56","author":"Berns","year":"1999","journal-title":"Kidney Int"},{"key":"2026021616021099200_hpaf200-B23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1525-1594.2005.00166.x","article-title":"The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, doppler, and tissue doppler echocardiographic parameters","volume":"29","author":"Kirkpantur","year":"2005","journal-title":"Artif Organs"},{"key":"2026021616021099200_hpaf200-B24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000507396","article-title":"Effects of erythropoietin-stimulating agents on blood pressure in patients with non-dialysis CKD and renal anemia","volume":"6","author":"Ohki","year":"2020","journal-title":"Kidney Dis (Basel)"},{"key":"2026021616021099200_hpaf200-B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf200\/64521932\/hpaf200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/3\/441\/64521932\/hpaf200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/3\/441\/64521932\/hpaf200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:02:20Z","timestamp":1771275740000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/3\/441\/8276119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf200","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,6]]}}}